← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
HomeStocksPTCTEarnings History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

PTCT logoPTC Therapeutics, Inc. (PTCT) Earnings History

Annual and quarterly earnings data from 2011 to 2025

TTM Net Income
-$187M
Net Loss
TTM EPS
$-2.26
Diluted
YoY EPS Growth
+264.5%
Excellent
Net Margin
39.4%
Profitability
Operating Margin49.5%
Gross Margin95.9%
ROEN/A
ROA29.6%
Highest Annual Net Income$683M (2025)
Highest Quarterly EPS$10.04 (Q1 2025)
Consecutive Profitable Years1 years
Q1 2026
Net Income-$3M
EPS$-0.03
QoQ Growth+97.9%Excellent

Loading earnings history...

PTCT EPS Growth (CAGR)

Compound annual growth rate of diluted earnings per share

1-Year
N/A
N/M
3-Year
N/A
N/M
5-Year
N/A
N/M
10-Year
N/A
N/M

CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.

PTCT Profitability Analysis

Margin trends over time

View revenue breakdown →
YearGross MarginOperating MarginNet Margin
202595.9%49.5%39.4%
202492.9%-37.5%-45.0%
202393.0%-46.9%-66.8%
202293.6%-64.0%-80.0%
202194.0%-69.5%-97.3%
Gross Margin = Gross Profit ÷ Revenue
Operating Margin = Operating Income ÷ Revenue
Net Margin = Net Income ÷ Revenue

Download Data

Export PTCT earnings history in CSV or JSON format

Free sign-in required to download data

PTC Therapeutics, Inc. (PTCT) Earnings Overview

As of May 8, 2026, PTC Therapeutics, Inc. (PTCT) reported trailing twelve-month net income of -$187M, reflecting +264.5% year-over-year growth. The company earned $-2.26 per diluted share over the past four quarters, with a net profit margin of 39.4%.

Looking at the long-term picture, PTCT's historical earnings data spans multiple years. The company achieved its highest annual net income of $683M in fiscal 2025, representing a new all-time high.

PTC Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including SRPT ($65M net income, -32.5% margin), BMRN ($269M net income, 10.8% margin), RARE (-$609M net income, -85.4% margin), PTCT has outperformed on profitability metrics. Compare PTCT vs SRPT →

PTCT Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
PTCT logoPTCTCurrent
-$187M$-2.2639.4%-+264.5%—
SRPT logoSRPT
$65M$0.53-32.5%-53.5%-404.7%
BMRN logoBMRN
$269M$1.3610.8%5.9%-18.6%
RARE logoRARE
-$609M$-6.06-85.4%-607.5%+7.3%
ALNY logoALNY
$577M$4.188.4%73.3%+206.9%
ACAD logoACAD
$376M$2.1836.5%39.9%+68.4%
Best in group
Lowest in group

PTCT Historical Earnings Data (2011–2025)

15 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025$683M+287.9%$857M$7.7839.4%49.5%
2024-$363M+42.0%-$303M$-4.73-45.0%-37.5%
2023-$627M-12.1%-$440M$-8.37-66.8%-46.9%
2022-$559M-6.7%-$447M$-7.79-80.0%-64.0%
2021-$524M-19.6%-$374M$-7.43-97.3%-69.5%
2020-$438M-74.2%-$432M$-6.64-115.1%-113.4%
2019-$252M-96.4%-$241M$-4.27-82.0%-78.6%
2018-$128M-62.1%-$116M$-2.75-48.4%-43.7%
2017-$79M+44.4%-$64M$-2.02-40.6%-33.1%
2016-$142M+16.6%-$132M$-4.17-171.8%-159.7%

See PTCT's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is PTCT Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare PTCT vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

PTCT — Frequently Asked Questions

Quick answers to the most common questions about buying PTCT stock.

Is PTCT growing earnings?

PTCT EPS is $-2.26, with earnings growth accelerating to +264.5%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-187M.

What are PTCT's profit margins?

PTC Therapeutics, Inc. net margin is +39.4%, with operating margin at +49.5%. Above-average margins indicate pricing power.

How consistent are PTCT's earnings?

PTCT earnings data spans 2011-2025. The accelerating earnings trend is +264.5% YoY. Historical data enables comparison across business cycles.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

PTCT Earnings Over Time (2014–2025)

Net income and EPS trends